Biogen Idec

Kapa Biosystems is a biotechnology company based in Wilmington, MA, with a presence in the United Kingdom and Europe. Specializing in PCR reagents and supplies, the company offers a wide range of products for applications such as high-fidelity PCR, miRNA qPCR, and single-cell sequence amplification. Their product line includes innovative solutions like the AffiPCR 2X PCR Mix and AffiPCR Bst2.0 HS 8U L, designed for various PCR applications including direct blood PCR and methyl sequencing. With a focus on quality and efficiency, Kapa Biosystems provides cutting-edge tools for researchers in the biotechnology and life sciences industries.Generated from the website

Saint-Gobain Ceramics & Plastics Northboro research and development center is part of an international company that has been in operation for over 300 years, originally founded in France. Specializing in producing innovative materials, construction products, high-tech materials, and plasterboard, the company is at the forefront of developing cutting-edge solutions for various industries. Located in Northborough, MA, the Saint-Gobain facility serves as a hub for research and development, driving forward advancements in materials science and technology. With a focus on innovation and quality, the company continues to lead the way in creating products that meet the evolving needs of the modern world. Generated from their available business information

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.